Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 6.2% – Time to Sell?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price traded down 6.2% during mid-day trading on Wednesday . The company traded as low as $38.10 and last traded at $38.25. 234,243 shares changed hands during trading, a decline of 25% from the average session volume of 313,650 shares. The stock had previously closed at $40.76.

Analyst Upgrades and Downgrades

MAZE has been the subject of a number of analyst reports. Wells Fargo & Company began coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price target for the company. BTIG Research lifted their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a report on Friday, September 12th. Wedbush increased their target price on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics has a consensus rating of “Buy” and a consensus price target of $41.88.

Maze Therapeutics Stock Performance

The company has a market cap of $1.86 billion and a price-to-earnings ratio of -1.85. The business has a fifty day moving average price of $32.59 and a 200 day moving average price of $21.49.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Insider Activity

In related news, Director Richard H. Scheller sold 20,744 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. lifted its stake in shares of Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after acquiring an additional 438,274 shares during the last quarter. ARCH Venture Management LLC bought a new position in shares of Maze Therapeutics during the first quarter valued at $45,362,000. Matrix Capital Management Company LP acquired a new stake in shares of Maze Therapeutics in the first quarter valued at about $27,373,000. Vanguard Group Inc. lifted its position in shares of Maze Therapeutics by 218.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after purchasing an additional 915,342 shares during the period. Finally, Woodline Partners LP boosted its stake in shares of Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock valued at $26,843,000 after purchasing an additional 94,529 shares during the last quarter.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.